replimune.com (REPL) - Utang marang Ekuitas

The Replimune Group, Inc. (REPL) price chart on the GURU.Markets platform, where the debt-to-equity ratio stands at 1.10, highlights the complexities of operating under strict FDA oversight and high patenting costs. Drug discovery efficiency is enhanced here through the implementation of automated biomolecule screening systems. The business is based on the development of oncolytic viruses, which opens prospects for long-term revenue through collaborations with pharma behemoths.

REPL - Rasio Total Utang marang Ekuitas Replimune ing rentang 04.07.2022 - 28.10.2026

Rincian metrik komprehensif lan analitis Replimune Inc. (REPL)

- rega lan prakiraan konsensus rega:

Bagan rega Replimune|REPL - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Nilai pasar Replimune|REPL - Nilai Bisnis

- data kapitalisasi buku:

Nilai Buku saben Saham Replimune|REPL - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku replimune.com|REPL - Aset Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas Replimune Group, Inc.|REPL - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Replimune Group, Inc.|REPL - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Replimune|REPL - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan Replimune

Analisis dhasar perusahaan:Replimune (REPL)

Financial stability is critical for Replimune Group, Inc. (REPL) as it develops the RPx platform and implements therapeutic protocols. By analyzing the total debt-to-equity ratio, an investor assesses the proportion of borrowed capital within the business's financing structure. This metric compares total liabilities to net assets to determine the level of credit risk. The trend of this indicator reflects the pace of deleveraging or debt-funded expansion. A declining ratio confirms the company's autonomy in executing its oncology research.

Analisis perusahaan pesaing